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 Self vs. “nonself”
 Protection from infectious diseases
 Usually indicated by the presence of antibody
 Generally specific to a single organism
Immunity
 Live or inactivated substances (e.g., viruses, 
bacteria, toxins)
- Capable of stimulating an immune response
 Antigen = antibody generator
Antigen
Virus with antigens on surface
 Protein molecules (immunoglobulins)
- Produced by B cells (lymphocytes) to bind to a
corresponding antigen (lock and key mechanism)
- Helps neutralize antigen and prepare it for
destruction
- B cells develop in the bone marrow
Antibody
Antibodies
B-Cell
 Humoral
- Production of antibodies that are
specific to a certain antigen or group of
antigens
- Antibodies attach to invading organism
and interfere with its ability to produce
more invading organisms
Arms of the Immune System
Antibodies attaching to antigens 
Antigen
Antibody
Antibody
 Cell-mediated – T lymphocytes (T-cells)
- Involves the activation of T-cells, macrophages,
and other substances that eliminate the antigen
- T-cells mature in the thymus gland
Arms of the Immune System
T-Cell
Types of Immunity: Active and Passive 
 Transfer of antibody produced by one human or animal to another
 Temporary protection that wanes with time
 Transfer of antibody through placenta – important to protect infants
Passive Immunity
Passive Immunity Video 
 Many types of blood or blood products
 Homologous pooled human antibody (immune globulin or IG)
- IgG antibody from the blood of thousands of American adult donors
- Hepatitis A and measles postexposure prophylaxis (PEP)
Sources of Passive Immunity
 Homologous human hyperimmune globulin (e.g., HBIG)
- Taken from donors with high concentrations of a specific antibody
- HBIG, RIG, TIG, VariZIG, VIG
 Heterologous hyperimmune serum
- Antitoxin (e.g., diphtheria antitoxin)
- Serum sickness
Sources of Passive Immunity
 Monoclonal antibodies
- Derived from a single type, or clone, of antibody-producing cells (B cells)
• Immune globulin from human sources is polyclonal (contains many different
kinds of antibodies)
- Antibody is specific to a single antigen or closely related group of antigens
- Used for diagnosis of and therapy for certain cancers and autoimmune and
infectious diseases, as well as prevention of transplant rejection
-Monoclonal-antibody-derived drugs end in –mab (i.e., Palivizumab)
Sources of Passive Immunity
 Palivizumab (Synagis)
-Monoclonal
- Contains only RSV antibody
-Will not interfere with the response to a live-virus vaccine
Antibody for Prevention of RSV
 Protection produced by a person's own immune system
 Lasts for many years, often lifetime
Active Immunity
Active Immunity Video 
 Infection with disease-causing
form of organism
 Vaccination
Sources of Active Immunity
 Active immunity produced by vaccine
- Vaccine delivers a dead or attenuated (weakened, nonpathogenic)
form of the pathogen
 Immunity and immunologic memory similar to natural
infection but without risk of disease
- Immunologic memory allows for an anamnestic response after the
primary immune response so that antibody reappears when the
antigen is introduced
Vaccination
 Presence of maternal antibodies
 Nature and amount of antigen in vaccine
 Route of administration
 Presence of an adjuvant (ingredient that promotes a stronger
immune response)
 Storage and handling of vaccine
 Vaccinee
- Age
- Nutritional status
- Genetics
- Coexisting disease
Factors that Affect 
Immune Response to Vaccines
Classification
of 
Vaccines
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 Live, attenuated (weakened form of the organism)
• Viral or bacterial
 Inactivated (nonlive or fraction of the organism)
• Viral or bacterial
• Protein-based (e.g., toxoid or subunit vaccines)
• Polysaccharide based (e.g., bacterial cell wall polysaccharide)
Classification of Vaccines
Principles of 
Vaccination
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 General rule:  The more similar a vaccine is to the natural
disease, the better the immune response to the vaccine
Principles of Vaccination
Live Attenuated Vaccine Vidoe
 Attenuated (weakened) form of the "wild" virus or bacterium
 Must replicate to produce an immune response
 Immune response virtually identical to natural infection
 Usually produce immunity with 1 dose*
Live, Attenuated Vaccines
*Except those administered orally
Individual Response to Live Vaccine
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 When a significant
portion of the
population is  immune
and provides
protection for
individuals who are not
immune
Herd Immunity/
Community Immunity 
 Severe reactions possible
 Interference from circulating antibody
 Fragile – must be stored and handled carefully
Live, Attenuated Vaccines
 Viral
 Bacterial
MMR, varicella, zoster vaccine live 
(ZVL), yellow fever, rotavirus, LAIV 
(intranasal influenza), smallpox 
(vaccinia), oral adenovirus, oral 
polio*
BCG,** oral typhoid, oral cholera
Live, Attenuated Vaccines
* Not used in the United States
**Not used in the United States for routine TB protection
 Whole
– Viruses
– Bacteria
 Fractional
– Protein-based
• Toxoid
• Subunit
– Polysaccharide-based
• Pure
• Conjugate
Inactivated Vaccines
Inactivated Vaccine Video 
 Cannot replicate
 Less affected by circulating antibody than live vaccines
- Example:  HepB vaccine and HBIG for perinatal hepatitis B PEP
 Always require multiple doses
 Immune response mostly humoral
 Antibody titer diminishes with time
 May require periodic supplemental doses
Inactivated Vaccines
Individual Response to Inactivated Vaccine
Protective level
0
10
20
30
40
50
60
70
80
90
100
Pre Post 1 Post 2 Post 3 Post 4 5 yrs
An
tib
od
y
le
ve
l
Dose
Population Response to Inactivated Vaccine
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 Whole
– Viral
• Polio, hepatitis A, rabies, Japanese encephalitis, and
influenza*
– Bacterial
• Pertussis,* typhoid,* cholera,* plague*
Inactivated Vaccines
*Not available in the United States
 Fractional
– Subunit
• Hepatitis B, influenza, acellular pertussis, human papillomavirus, and
anthrax
• Polysaccharide vaccines
– Toxoid
• Diphtheria, tetanus
Inactivated Vaccines
Capsular Polysaccharide
Capsular Polysaccharide
 Immune response typically T-cell-independent
 Not consistently immunogenic in children younger than 2 years of age
 No booster response
 Antibody with less functional activity (IgM rather than IgG)
 Immunogenicity improved by conjugation
Pure Polysaccharide Vaccines
 Pure polysaccharide
– Pneumococcal (PPSV23)
– Salmonella Typhi (Vi)
 Conjugate polysaccharide
– Haemophilus influenzae type b (Hib)
– Pneumococcal (PCV13)
– Meningococcal
Polysaccharide Vaccines
 Viral:  hepatitis B, human papillomavirus, influenza (RIV), influenza
(LAIV), and rotavirus (RV5)
 Bacterial:  meningococcal B
Genetically Engineered Vaccines
New Design for Schedule Web Pages
Recommended Immunization Schedules for Health Care Providers www.cdc.gov/vaccines/schedules/index.html Accessed 5/31/2019
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 Comprehensive list of resources for
ALL the webinars
 Located on the webpage for this
webinar with the:
– Webinar slides
– Archived recast
– Webinar questions and answers
– Transcript
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